IntelliCell BioSciences Announces Michael Hershman Joins the IntelliCell BioSciences Board of Directors

NEW YORK, Nov. 26, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced today that Michael Hershman has joined the IntelliCell Board of Directors.

IntelliCell's Chairman and CEO, Dr. Steven Victor, stated, "Our Company is very pleased to announce today that Michael Hershman is joining our Board of Directors. His international experience and accomplishments will add a very significant capability to our Board and our Company. Mr. Hershman has long been recognized as one of the most influential business people worldwide and we are looking forward to working with him as we strengthen the IntelliCell executive management team with world class people."

Said Mr. Hershman, "I am delighted to join the Board of IntelliCell and assist this cutting edge medical technology company which holds the potential to improve the well being of millions of people globally. I look forward to working with Dr. Victor and other Board members to develop IntelliCell as a leading company in Regenerative Medicine and contribute my efforts to creating an outstanding organization."

About IntelliCell BioSciences
IntelliCell BioSciences is a Regenerative Medicine company developing novel technologies that address the regenerative, curative, and preventative conditions of disease states with high unmet clinical needs. The Company has several patent pending applications including an industry unique method of obtaining autologous stromal vascular fraction cells (SVF) from the vasculature surrounding adipose tissue containing adult stem cells and a robust population of regenerative healing cells. The Company is also pioneering the development of autologous and allogeneic cells from living and non-living tissue donors for research purposes. IntelliCell is planning a series of in-human clinical studies with top tier universities for the treatment of osteoarthritis, multiple sclerosis, lower limb ischemic wounds, and gum regeneration in the oral cavity as well as medical aesthetics. The Company has developed a first in class cGTP cellular processing facility in New York City, purpose built and designed to be fully integrated into its ambulatory surgery center.

About Michael Hershman
Michael Hershman is an internationally recognized expert on matters relating to transparency, accountability, governance, litigation and security. Immediately prior to founding the Fairfax Group, Mr. Hershman served as deputy auditor general for the Foreign Assistance Program of the U.S. Agency for International Development (AID), where he led investigations and audits of major U.S. funded projects overseas, and was responsible for worldwide security at all foreign AID missions. Mr. Hershman was awarded the Superior Honor Medal for his service at AID.

In 1993, along with Peter Eigen, Mr. Hershman co-founded Transparency International, the largest independent, not-for-profit coalition promoting transparency and accountability in business and in government. For the past 6 years he has served Interpol as a member of the International Group of Experts on Corruption, and for the past 12 years, he has sat on the board of the International Anti-Corruption Conference Committee.

Mr. Hershman is a member of the board of directors of the U.S. Chamber of Commerce Foundation, and advises the Chamber on corporate compliance issues. Since 2007, Mr. Hershman has been a member of the board of directors and the executive committee of the Center for International Private Enterprise.

For the past 12 years he has been a member of Interpol's International Group of Experts on Corruption and now serves as Vice Chairman. He is also on the board of the International Anti-Corruption Conference Committee. He also serves on the Financial Coalition against Child Pornography, a project of the National Center for Missing and Exploited Children. Additionally, he is a member of the Advisory Council of the George Mason University School of Information Technology and Engineering.

Since 2008, he has been named every consecutive year to the Ethisphere Institute's list of the top 100 most influential people in business ethics worldwide.

Michael Hershman has given hundreds of speeches throughout the world on issues related to transparency and accountability and has provided commentary on ABC, CBS, NBC, PBS, CNN, CNBC, MSNBC and the Fox News Channel as well as countless national radio shows. For five years he was the co-host of the Public Radio Law Show. He has been quoted and published in the Wall Street Journal, the New York Times, the New York Post, the Washington Post, USA Today, the Financial Times, the National Law Journal and other print media.

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contacts:

IntelliCell BioSciences, Inc.
Robert J. Sexauer
Email Contact: rsexauer@intellicellbiosciences.com
(646) 576-8706

SOURCE IntelliCell BioSciences, Inc.